# Sophie Postel-Vinay

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 60 papers | 5,700 citations | 172457 29 h-index | 133252 59 g-index |
| 64 all docs | 64 docs citations | 64 times ranked | 9820 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers. Cancer Research, 2022, 82, 969-971. | 0.9 | 3 |
| 2 | Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. Biomedicines, 2022, 10, 650. | 3.2 | 24 |
| 3 | Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232. | 4.2 | 12 |
| 4 | 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 847-859. | 0.9 | 7 |
| 5 | PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902. | 0.9 | 66 |
| 6 | Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2021, 27, 5213-5224. | 7.0 | 53 |
| 7 | Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717. | 28.4 | 150 |
| 8 | Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1039-1041. | 16.8 | 2 |
| 9 | Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Seminars in Cancer Biology, 2020, 61, 180-198. | 9.6 | 28 |
| 10 | Combining epigenetic drugs with other therapies for solid tumours â€" past lessons and future promise. Nature Reviews Clinical Oncology, 2020, 17, 91-107. | 27.6 | 283 |
| 11 | Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139. | 9.6 | 9 |
| 12 | Impact of COVID-19 Pandemic on Cancer Research. Cancer Cell, 2020, 38, 591-593. | 16.8 | 7 |
| 13 | Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126. | 2.8 | 16 |
| 14 | How Much Can We Bet on Activity of BET Inhibitors Beyond NUTâ€"Midline Carcinoma?. JNCI Cancer Spectrum, 2020, 4, pkz092. | 2.9 | 7 |
| 15 | Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncology, The, 2020, 21, 1155-1164. | 10.7 | 274 |
| 16 | Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?. European Journal of Cancer, 2020, 137, 235-239. | 2.8 | 7 |
| 17 | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652. | 2.8 | 21 |
| 18 | First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. British Journal of Cancer, 2020, 123, 1730-1736. | 6.4 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Beyond DNA repair: the novel immunological potential of PARP inhibitors. Molecular and Cellular Oncology, 2019, 6, 1-4. | 0.7 | 18 |
| 20 | First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. European Journal of Cancer, 2019, 109, 103-110. | 2.8 | 76 |
| 21 | Long-Term Survival in Patients Responding to Antiâ€“PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956. | 7.0 | 96 |
| 22 | PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228. | 8.2 | 222 |
| 23 | You BETer be aware â€“ learnings from a negative Phase 1 study. Oncotarget, 2019, 10, 3145-3146. | 1.8 | 0 |
| 24 | Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology, 2018, 29, 812-824. | 1.2 | 73 |
| 25 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open, 2018, 3, e000257. | 4.5 | 62 |
| 26 | Immune Therapies in Phase 1 Trials. , 2018, , 547-563. | | 0 |
| 27 | Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Investigational New Drugs, 2018, 36, 62-74. | 2.6 | 3 |
| 28 | Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. British Journal of Cancer, 2018, 119, 937-939. | 6.4 | 7 |
| 29 | DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation, 2018, 128, 1671-1687. | 8.2 | 19 |
| 30 | Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750. | 1.8 | 12 |
| 31 | JAK Mutations as Escape Mechanisms to Antiâ€“PD-1 Therapy. Cancer Discovery, 2017, 7, 128-130. | 9.4 | 24 |
| 32 | High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595. | 9.4 | 554 |
| 33 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncology, The, 2017, 18, 1590-1599. | 10.7 | 535 |
| 34 | Prognostic factors and outcome of patients with hematological malignancies in phase I trials. Anti-Cancer Drugs, 2017, 28, 540-545. | 1.4 | 1 |
| 35 | In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. European Journal of Cancer, 2017, 87, 65-74. | 2.8 | 19 |
| 36 | Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open, 2017, 2, e000148. | 4.5 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research, 2017, 23, 1920-1928. | 7.0 | 960 |
| 38 | Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2017, 23, 2423-2432. | 7.0 | 50 |
| 39 | A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS ONE, 2016, 11, e0154895. | 2.5 | 10 |
| 40 | Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321. | 7.0 | 182 |
| 41 | Patients aged over 75 years enrolled in Phase I clinical trials: the <scp>G</scp>ustave <scp>R</scp>oussy experience. International Journal of Cancer, 2016, 138, 875-880. | 5.1 | 5 |
| 42 | Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. International Journal of Cardiology, 2016, 214, 364-369. | 1.7 | 0 |
| 43 | Chromatin Regulators as a Guide for Cancer Treatment Choice. Molecular Cancer Therapeutics, 2016, 15, 1768-1777. | 4.1 | 18 |
| 44 | Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clinical Cancer Research, 2016, 22, 2960-2968. | 7.0 | 103 |
| 45 | Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. Journal of Thoracic Oncology, 2016, 11, e21-e23. | 1.1 | 8 |
| 46 | Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology, 2016, 27, 214-224. | 1.2 | 86 |
| 47 | Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Annals of Oncology, 2016, 27, 344-352. | 1.2 | 9 |
| 48 | Targeting FGFR Signaling in Cancer. Clinical Cancer Research, 2015, 21, 2684-2694. | 7.0 | 399 |
| 49 | Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. Blood, 2015, 126, 473-473. | 1.4 | 37 |
| 50 | Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European Journal of Cancer, 2014, 50, 2050-2056. | 2.8 | 63 |
| 51 | Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents â€“ Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. European Journal of Cancer, 2014, 50, 2040-2049. | 2.8 | 104 |
| 52 | ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle, 2013, 12, 3298-3306. | 2.6 | 37 |
| 53 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature Reviews Clinical Oncology, 2012, 9, 144-155. | 27.6 | 96 |
| 54 | AXL and acquired resistance to EGFR inhibitors. Nature Genetics, 2012, 44, 835-836. | 21.4 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327. | 21.4 | 160 |
| 56 | Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 423-429. | 2.3 | 14 |
| 57 | Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?. Journal of Clinical Oncology, 2011, 29, 1728-1735. | 1.6 | 120 |
| 58 | Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today, 2010, 15, 88-97. | 6.4 | 69 |
| 59 | Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncology, The, 2010, 11, 129-135. | 10.7 | 334 |
| 60 | Reovirus: Rationale and clinical trial update. Current Opinion in Molecular Therapeutics, 2009, 11, 532-9. | 2.8 | 25 |